Preexisting immunity: Barrier or bridge to effective oncolytic virus therapy?

IF 9.3 2区医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY

Cytokine & Growth Factor Reviews Pub Date : 2023-04-01 DOI:10.1016/j.cytogfr.2023.01.002

Christianne Groeneveldt , Jasper van den Ende , Nadine van Montfoort

{"title":"Preexisting immunity: Barrier or bridge to effective oncolytic virus therapy?","authors":"Christianne Groeneveldt , Jasper van den Ende , Nadine van Montfoort","doi":"10.1016/j.cytogfr.2023.01.002","DOIUrl":null,"url":null,"abstract":"<div><p>Oncolytic viruses (OVs) represent a highly promising treatment strategy for a wide range of cancers, by mediating both the direct killing of tumor cells as well as mobilization of antitumor immune responses. As many OVs circulate in the human population, preexisting OV-specific immune responses are prevalent. Indeed, neutralizing antibodies (NAbs) are abundantly present in the human population for commonly used OVs, such as Adenovirus type 5 (Ad5), Herpes Simplex Virus-1 (HSV-1), Vaccinia virus, Measles virus, and Reovirus. This review discusses (pre)clinical evidence regarding the effect of preexisting immunity against OVs on two distinct aspects of OV therapy; OV infection and spread, as well as the immune response induced upon OV therapy. Combined, this review provides evidence that consideration of preexisting immunity is crucial in realizing the full potential of the highly promising therapeutic implementation of OVs. Future investigation of current gaps in knowledge highlighted in this review should yield a more complete understanding of this topic, ultimately allowing for better and more personalized OV therapies.</p></div>","PeriodicalId":11132,"journal":{"name":"Cytokine & Growth Factor Reviews","volume":null,"pages":null},"PeriodicalIF":9.3000,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cytokine & Growth Factor Reviews","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1359610123000023","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 3

Abstract

Oncolytic viruses (OVs) represent a highly promising treatment strategy for a wide range of cancers, by mediating both the direct killing of tumor cells as well as mobilization of antitumor immune responses. As many OVs circulate in the human population, preexisting OV-specific immune responses are prevalent. Indeed, neutralizing antibodies (NAbs) are abundantly present in the human population for commonly used OVs, such as Adenovirus type 5 (Ad5), Herpes Simplex Virus-1 (HSV-1), Vaccinia virus, Measles virus, and Reovirus. This review discusses (pre)clinical evidence regarding the effect of preexisting immunity against OVs on two distinct aspects of OV therapy; OV infection and spread, as well as the immune response induced upon OV therapy. Combined, this review provides evidence that consideration of preexisting immunity is crucial in realizing the full potential of the highly promising therapeutic implementation of OVs. Future investigation of current gaps in knowledge highlighted in this review should yield a more complete understanding of this topic, ultimately allowing for better and more personalized OV therapies.

Abstract Image

查看原文本刊更多论文

先前存在的免疫:有效溶瘤病毒治疗的屏障还是桥梁?

溶瘤病毒（OVs）通过介导肿瘤细胞的直接杀伤和抗肿瘤免疫反应的动员，代表了一种非常有前途的治疗多种癌症的策略。由于许多OV在人类中传播，先前存在的OV特异性免疫反应普遍存在。事实上，中和抗体（NAb）大量存在于人类群体中，用于常见的OV，如5型腺病毒（Ad5）、单纯疱疹病毒-1（HSV-1）、痘苗病毒、麻疹病毒和呼肠孤病毒。这篇综述讨论了关于先前存在的对OV的免疫力对OV治疗的两个不同方面的影响的（前）临床证据；OV感染和传播，以及OV治疗诱导的免疫反应。综合来看，这篇综述提供了证据，证明考虑预先存在的免疫力对于充分发挥OVs极具前景的治疗潜力至关重要。未来对本综述中强调的当前知识差距的调查应能更全面地了解这一主题，最终实现更好、更个性化的OV治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cytokine & Growth Factor Reviews 生物-生化与分子生物学

CiteScore

21.10

自引率

1.50%

发文量

审稿时长

22 days

期刊介绍： Cytokine & Growth Factor Reviews is a leading publication that focuses on the dynamic fields of growth factor and cytokine research. Our journal offers a platform for authors to disseminate thought-provoking articles such as critical reviews, state-of-the-art reviews, letters to the editor, and meeting reviews. We aim to cover important breakthroughs in these rapidly evolving areas, providing valuable insights into the multidisciplinary significance of cytokines and growth factors. Our journal spans various domains including signal transduction, cell growth and differentiation, embryonic development, immunology, tumorigenesis, and clinical medicine. By publishing cutting-edge research and analysis, we aim to influence the way researchers and experts perceive and understand growth factors and cytokines. We encourage novel expressions of ideas and innovative approaches to organizing content, fostering a stimulating environment for knowledge exchange and scientific advancement.